Abstract
Introduction
Gynecological cancers account for a large number of cancer-related deaths in women. Endometrial cancer is the most prevalent, while ovarian cancer is the deadliest gynecological cancer worldwide. To overcome the clinical need for easy and rapid testing, there is a growing interest in cancer detection in non-invasive modalities. With a growing field of liquid biopsy, urine became interesting source of cancer biomarkers.
Objectives
The aim of this manuscript is to provide an overview on the origin, analysis and the clinical significance of urine microRNAs in gynecological cancers, with a focus on ovarian and endometrial cancer. MicroRNAs, a class of small non-coding nucleic acids, are emerging as a non-invasive biomarkers due to the feasibility and the extreme stability in body fluids. Specific miRNA expression signatures have been previously identified in ovarian and endometrial cancer.
Results
The aim of this manuscript is to provide an overview on the origin, analysis and the clinical significance of urine microRNAs in gynecological cancers, with the focus on ovarian and endometrial cancer.
Conclusion
The advantages and limitations of urine microRNA utility and technologies are discussed. Previously detected microRNA from urine of the patients are summarized to evaluate their potential as non-invasive clinical biomarkers in gynecological oncology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not required for this type of study.
References
Alix-Panabières C, Pantel K (2021) Liquid biopsy: from discovery to clinical application. Cancer Discov 11(4):858–873. https://doi.org/10.1158/2159-8290.CD-20-1311
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108(12):5003–5008. https://doi.org/10.1073/pnas.1019055108
Ayaz L, Çayan F, Balci Ş, Görür A, Akbayir S, YıldırımYaroğlu H, DoğruerUnal N, Tamer L (2014) Circulating microRNA expression profiles in ovarian cancer. J Obstet Gynaeco 34(7):620–624. https://doi.org/10.3109/01443615.2014.919998
Beltrami C, Clayton A, Newbury LJ, Corish P, Jenkins RH, Phillips AO, Fraser DJ, Bowen T (2015) Stabilization of urinary microRNAs by association with exosomes and argonaute 2 protein. Noncoding RNA 1(2):151–166. https://doi.org/10.3390/ncrna1020151
Berek JS, Friedlander ML, Hacker NF (2014) Epithelial ovarian, fallopian tube, and peritoneal cancer. In: Berek and Hacker’s Gynecologic Oncology: Sixth Edition. Wolters Kluwer Health Adis (ESP), 464–529. https://doi.org/10.1002/9781119000822.hfcm105
Berner K, Hirschfeld M, Weiß D, Rücker G, Asberger J, Ritter A, Nöthling C, Jäger M, Juhasz-Böss I, Erbes T (2022) Evaluation of circulating microRNAs as non-invasive biomarkers in the diagnosis of ovarian cancer—a case-control study. Arch Gynecol Obstet 306(1):151–163. https://doi.org/10.1007/s00404-021-06287-1
Borchert GM, Lanier W, Davidson BL (2006) RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13(12):1097–1101. https://doi.org/10.1038/nsmb1167
Braun MM, Overbeek-Wager EA, Grumbo RJ (2016) Diagnosis and management of endometrial cancer. Am Fam Physician 93(6):468–474
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Cao Q, Lu K, Dai S, Hu Y, Fan W (2014) Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. Int J Clin Exp Pathol 7(5):2392–2401
Catto JW, Alcaraz A, Bjartell AS, De Vere WR, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) Eur Urol 59(5):671–681. https://doi.org/10.1016/j.eururo.2011.01.044
Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, Boussios S (2022) Non-epithelial ovarian cancers: how much do we really know? Int J Environ Res Public Health 19(3):1106. https://doi.org/10.3390/ijerph19031106
Delangle R, De Foucher T, Larsen AK, Sabbah M, Azaïs H, Bendifallah S, Daraï E, Ballester M, Mehats C, Uzan C, Canlorbe G (2019) The use of microRNAs in the management of endometrial cancer: a meta-analysis. Cancers (Basel) 11(6):832. https://doi.org/10.3390/cancers11060832
Desvignes T, Batzel P, Berezikov E, Eilbeck K, Eppig JT, McAndrews MS, Singer A, Postlethwait JH (2015) MiRNA nomenclature: a view incorporating genetic origins, biosynthetic pathways, and sequence variants. Trends Genet 31(11):613–626. https://doi.org/10.1016/j.tig.2015.09.002
Di Meo A, Brown MD, Finelli A, Jewett MAS, Diamandis EP, Yousef GM (2020) Prognostic urinary miRNAs for the assessment of small renal masses. Clin Biochem 75:15–22. https://doi.org/10.1016/j.clinbiochem.2019.10.002
Donkers H, Hirschfeld M, Weiß D, Erbes T, Jäger M, Pijnenborg J, Bekkers R, Galaal K (2021) Detection of microRNA in urine to identify patients with endometrial cancer: a feasibility study. Int J Gynecol Cancer 31(6):868–874. https://doi.org/10.1136/ijgc-2021-002494
Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk MA, Mischak H, Vlahou A, Theodorescu D, Merseburger AS (2014) Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J Proteomics 98:44–58. https://doi.org/10.1016/j.jprot.2013.12.010
Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, Ørntoft TF, Sørensen KD (2018) Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus 4(6):825–833. https://doi.org/10.1016/j.euf.2017.02.018
Ghafouri-Fard S, Shoorei H, Taheri M (2020) miRNA profile in ovarian cancer. Exp Mol Pathol 113:104381. https://doi.org/10.1016/j.yexmp.2020.104381
Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E, Boussios S (2022) Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes 10(2):16. https://doi.org/10.3390/proteomes10020016
Grayson K, Gregory E, Khan G, Guinn B-A (2019) Urine biomarkers for the early detection of ovarian cancer—are we there yet? Biomark Cancer 11:1179299X19830977. https://doi.org/10.1177/1179299X19830977
Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28(6):655–661. https://doi.org/10.1016/j.urolonc.2009.01.027
Harpole M, Davis J, Espina V (2016) Current state of the art for enhancing urine biomarker discovery. Expert Rev Proteomics 13(6):609–626. https://doi.org/10.1080/14789450.2016.1190651
Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J (2019) The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol 58(3):342–352. https://doi.org/10.1080/0284186X.2018.1540886
**g J, Gao Y (2018) Urine biomarkers in the early stages of diseases: current status and perspective. Discov Med 5(136):57–65
Jordaens S, Zwaenepoel K, Tjalma W, Deben C, Beyers K, Vankerckhoven V, Pauwels P, Vorsters A (2023) Urine biomarkers in cancer detection: a systematic review of preanalytical parameters and applied methods. Int J Cancer. https://doi.org/10.1002/ijc.34434
Juracek J, Madrzyk M, Stanik M, Slaby O (2022) Urinary microRNAs and their significance in prostate cancer diagnosis: a 5-year update. Cancers (Basel) 14(13):3157. https://doi.org/10.3390/cancers14133157
Kappel A, Keller A (2017) miRNA assays in the clinical laboratory: workflow, detection technologies and automation aspects. Clin Chem Lab Med 55(5):636–647. https://doi.org/10.1515/cclm-2016-0467
Kinose Y, Sawada K, Nakamura K, Kimura T (2014) The role of MicroRNAs in ovarian cancer. Biomed Res Int. https://doi.org/10.1155/2014/249393
Koutsaki M, Libra M, Spandidos DA, Zaravinos A (2017) The miR-200 family in ovarian cancer. Oncotarget 8(39):66629–66640. https://doi.org/10.18632/oncotarget.18343
Kwok R, Johnson NP (2012) Ovarian biopsy has no role as a routine diagnostic test of ovarian reserve: a systematic review. Reprod Biomed Online 24(5):492–495. https://doi.org/10.1016/j.rbmo.2012.01.020
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi24-32. https://doi.org/10.1093/annonc/mdt333
Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23(20):4051–4060. https://doi.org/10.1038/sj.emboj.7600385
Lortet-Tieulent J, Ferlay J, Bray F, Jemal A (2018) International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 110(4):354–361. https://doi.org/10.1093/jnci/djx214
MacFarlane L-A, Murphy RP (2010) MicroRNA: biogenesis, function and role in cancer. Curr Genom 11(7):537–561. https://doi.org/10.2174/138920210793175895
Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A (2021) Endometrial cancer. Nat Rev Dis Primers 7(1):88. https://doi.org/10.1038/s41572-021-00324-8
Mall C, Rocke DM, Durbin-Johnson B, Weiss RH (2013) Stability of miRNA in human urine supports its biomarker potential. Biomark Med 7(4):623–631. https://doi.org/10.2217/bmm.13.44
Meden H, Fattahi-Meibodi A (1998) CA125 in benign gynecological conditions. Int J Biol Markers 13(4):231–237. https://doi.org/10.1177/172460089801300411
Menon U, Karpinskyj C, Gentry-Maharaj A (2018) Ovarian cancer prevention and screening. Obstet Gynecol 131(5):909–927. https://doi.org/10.1097/AOG.0000000000002580
Mlcochova H, Hezova R, Meli AC, Slaby O (2015) Urinary microRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology. Methods Mol Biol 1218:439–463. https://doi.org/10.1007/978-1-4939-1538-5_26
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ (2009) A Novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40–46. https://doi.org/10.1016/j.ygyno.2008.08.031
O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 9:402. https://doi.org/10.3389/fendo.2018.00402
O’Laughlin DJ, Strelow B, Fellows N, Kelsey E, Peters S, Stevens J, Tweedy J (2021) Addressing anxiety and fear during the female pelvic examination. J Prim Care Community Health 12:2150132721992195. https://doi.org/10.1177/2150132721992195
Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, Rashid OM, Matsuyama R, Endo I, Takabe K (2021) Urine as a source of liquid biopsy for cancer. Cancers (Basel) 13(11):2652. https://doi.org/10.3390/cancers13112652
Otmani K, Lewalle P (2021) Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol 11:708765. https://doi.org/10.3389/fonc.2021.708765
Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K, Schwarzenbach H (2018) Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol 12(11):1935–1948. https://doi.org/10.1002/1878-0261.12371
Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P (2020) Hsa-miR-155-5p Up-regulation in breast cancer and its relevance for treatment with poly[ADP-Ribose] polymerase 1 (PARP-1) inhibitors. Front Oncol 10:1415. https://doi.org/10.3389/fonc.2020.01415
Peng Y, Croce CM (2016) The role of microRNAs in human cancer. Signal Transduct Target Ther 1:15004. https://doi.org/10.1038/sigtrans.2015.4
Plotnikova O, Baranova A, Skoblov M (2019) Comprehensive analysis of human microRNA–mRNA interactome. Front Genet 10:933. https://doi.org/10.3389/fgene.2019.00933
Reichholf B, Herzog VA, Fasching N, Manzenreither RA, Sowemimo I, Ameres SL (2019) Time-resolved small RNA sequencing unravels the molecular principles of microRNA homeostasis. Mol Cell 75(4):756-768.e7. https://doi.org/10.1016/j.molcel.2019.06.018
Ritter A, Hirschfeld M, Berner K, Jaeger M, Grundner-Culemann F, Schlosser P, Asberger J, Weiss D, Noethling C, Mayer S, Erbes T (2020) Discovery of potential serum and urine-based microRNA as minimally-invasive biomarkers for breast and gynecological cancer. Cancer Biomark 27(2):225–242. https://doi.org/10.3233/CBM-190575
Roman-Canal B, Moiola CP, Gatius S, Bonnin S, Ruiz-Miró M, González E, González-Tallada X, Llordella I, Hernández I, Porcel JM, Gil-Moreno A, Falcón-Pérez JM, Ponomarenko J, Matias-Guiu X, Colas E (2019) EV-associated miRNAs from peritoneal lavage are a source of biomarkers in endometrial cancer. Cancers (Basel) 11(6):839. https://doi.org/10.3390/cancers11060839
Ruskin R, Srivastava A, McMeekin DS, Ramesh R, Moxley K (2016) Liquid gold: urinary exosomes as a potential source of biomarkers in endometrial cancer. Gynecol Oncol 143(1):207. https://doi.org/10.1016/j.ygyno.2016.08.272
Sagar SK (2021) miR-106b as an emerging therapeutic target in cancer. Genes Dis 9(4):889–899. https://doi.org/10.1016/j.gendis.2021.02.002
Saini HK, Griffiths-Jones S, Enright AJ (2007) Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A 104(45):17719–17724. https://doi.org/10.1073/pnas.0703890104
Satyal U, Srivastava A, Abbosh PH (2019) Urine biopsy—liquid gold for molecular detection and surveillance of bladder cancer. Front Oncol 9:1266. https://doi.org/10.3389/fonc.2019.01266
Savolainen K, Scaravilli M, Ilvesmäki A, Staff S, Tolonen T, Mäenpää JU, Visakorpi T, Auranen A (2020) Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes 13(1):311. https://doi.org/10.1186/s13104-020-05155-6
Saxby H, Mikropoulos C, Boussios S (2020) An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer. Diagnostics (Basel) 10(8):549. https://doi.org/10.3390/diagnostics10080549
Schaafsma M, van den Helder R, Bleeker MCG, Rosier-van Dunné F, van der Avoort IAM, Steenbergen RDM, van Trommel NE (2022) Experiences and preferences towards collecting a urine and cervicovaginal self-sample among women attending a colposcopy clinic. Prev Med Rep 26:101749. https://doi.org/10.1016/j.pmedr.2022.101749
Shah S, Cheung A, Kutka M, Sheriff M, Boussios S (2022) Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health 19(13):8113. https://doi.org/10.3390/ijerph19138113
Sohel MH (2016) Extracellular/circulating microRNAs: release mechanisms, functions and challenges. Achiev Life Sci 10(2):175–186. https://doi.org/10.1016/j.als.2016.11.007
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, KantyKulpa J, Tuxen MK, Molina R (2016) Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer 26(1):43–51. https://doi.org/10.1097/IGC.0000000000000586
Srivastava A, Moxley K, Ruskin R, Dhanasekaran DN, Zhao YD, Ramesh R (2018) A non-invasive liquid biopsy screening of urine-derived exosomes for miRNAs as biomarkers in endometrial cancer patients. AAPS J 20(5):82. https://doi.org/10.1208/s12248-018-0220
Staicu CE, Predescu D-V, Rusu CM, Radu BM, Cretoiu D, Suciu N, Crețoiu SM, Voinea S-C (2020) Role of microRNAs as clinical cancer biomarkers for ovarian cancer: a short overview. Cells 9(1):169. https://doi.org/10.3390/cells9010169
Thomas MJ, Fraser DJ, Bowen T (2018) Biogenesis, stabilization, and transport of microRNAs in kidney health and disease. Non-Coding RNA 4(4):30. https://doi.org/10.3390/ncrna4040030
Vasilatou D, Sioulas VD, Pappa V, Papageorgiou SG, Vlahos NF (2015) The role of miRNAs in endometrial cancer. Epigenomics 7(6):951–959. https://doi.org/10.2217/epi.15.41
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13(4):423–433. https://doi.org/10.1038/ncb2210
VilmingElgaaen B, Olstad OK, Haug KBF, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014) Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer 14:80. https://doi.org/10.1186/1471-2407-14-80
Wang Y, Qiu C, Lu N, Liu Z, ** C, Sun C, Bu H, Yu H, Dongol S, Kong B (2018) FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. Int J Oncol 52(6):2130–2142. https://doi.org/10.3892/ijo.2018.4359
Wang L, Zhao S, Yu M (2019) Mechanism of low expression of miR-30a-5p on epithelial-mesenchymal transition and metastasis in ovarian cancer. DNA Cell Biol 38(4):341–351. https://doi.org/10.1089/dna.2018.4396
Wang Y, Chen A, Zheng C, Zhao L (2021) miR-92a promotes cervical cancer cell proliferation, invasion, and migration by directly targeting PIK3R1. J Clin Lab Anal 35(8):e23893. https://doi.org/10.1002/jcla.23893
Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56(11):1733–1741. https://doi.org/10.1373/clinchem.2010.147405
Wilczynski M, Danielska J, Domanska-Senderowska D, Dzieniecka M, Szymanska B, Malinowski A (2018) Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer. Acta Obstet Gynecol Scand 97(5):560–569. https://doi.org/10.1111/aogs.13306
Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009) Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat Cell Biol 11(3):228–234. https://doi.org/10.1038/ncb0309-228
Yanokura M, Banno K, Kobayashi Y, Kisu I, Ueki A, Ono A, Masuda K, Nomura H, Hirasawa A, Susumu N, Aoki D (2010) MicroRNA and endometrial cancer: roles of small RNAs in human tumors and clinical applications (Review). Oncol Lett 6:935–940. https://doi.org/10.3892/ol.2010.173
Ye J, Xu M, Tian X, Cai S, Zeng S (2019) Research advances in the detection of miRNA. J Pharm Anal 9(4):217–226. https://doi.org/10.1016/j.jpha.2019.05.004
Záveský L, Jandáková E, Turyna R, Langmeierová L, Weinberger V, ZáveskáDrábková L, Hůlková M, Hořínek A, Dušková D, Feyereisl J, Minář L, Kohoutová M (2015) Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study. Pathol Oncol Res 21(4):1027–1035. https://doi.org/10.1007/s12253-015-9914-y
Záveský L, Jandáková E, Weinberger V, Minář L, Hanzíková V, Dušková D, ZáveskáDrábková L, Svobodová I, Hořínek A (2019) Ascites-derived extracellular microRNAs as potential biomarkers for ovarian cancer. Reprod Sci 26(4):510–522. https://doi.org/10.1177/1933719118776808
Zhang DZ, Lau KM, Chan ESY, Wang G, Szeto CC, Wong K, Choy RKW, Ng CF (2014) Cell-free urinary MicroRNA-99a and MicroRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS ONE 9(7):e100793. https://doi.org/10.1371/journal.pone.0100793
Zhao C, Sun X, Li L (2019) Biogenesis and function of extracellular miRNAs. ExRNA 1:38. https://doi.org/10.1186/s41544-019-0039-4
Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, Wang J, Liu Y, Chen P, Wu X, Wen J (2015) Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep 33(6):2915–2923. https://doi.org/10.3892/or.2015.3937
Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A (2015) Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol 17(10):779–787. https://doi.org/10.1007/s12094-015-1303-1
Acknowledgements
This research is funded by La Région Occitanie (CARIBOU project), Université de Nîmes and the UPR CHROME from Université de Nîmes, France. The authors would like to thank La Région Occitanie for the support and Ecole de l’ADN de Nîmes for the contribution in the conceptualizations of figures using Biorender.com.
Funding
This research is funded by La Région Occitanie (CARIBOU project), the Université de Nîmes and the UPR CHROME from Université de Nîmes, France.
Author information
Authors and Affiliations
Contributions
AH and A-CED had the idea for the manuscript. The first draft of the manuscript was written by AH. A-CED and CS critically revised the work. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent and ethical approval
Not required for this type of study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hanžek, A., Siatka, C. & Duc, AC.E. Extracellular urinary microRNAs as non-invasive biomarkers of endometrial and ovarian cancer. J Cancer Res Clin Oncol 149, 7981–7993 (2023). https://doi.org/10.1007/s00432-023-04675-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-04675-5